Complete Remission Predicts for Long Survival of Patients with Multiple Myeloma(3/12/2010) Researchers from the M. D. Anderson Cancer Center have reported that achieving a complete remission (CR) was the dominant prognostic factor for long survival of patients with multiple myeloma (MM). The details of this large retrospective review were published in the March 2010 issue of Bone Marrow Transplantation.
Velcade® Effective in Patients with Systemic Amyloidosis(1/27/2010) Researchers from Greece, the UK, and Italy have reported that Velcade® (bortezomib) with or without dexamethasone is active for treatment of primary systemic light chain amyloidosis. The details of this study appeared in an early online publication in the Journal of Clinical Oncology on January 19, 2010.
Early Treatment of Smoldering Multiple Myeloma May Be of Benefit(12/30/2009) Researchers from Spain and Portugal have reported that compared with delayed therapy, early treatment of smoldering (asymptomatic) multiple myeloma (MM) may benefit patients at risk of progression to symptomatic MM. The details of this study were presented at the 2009 meeting of the American Society of Hematology in New Orleans in early December.
Velcade® Consolidation Improves Response Rate After High-dose Melphalan for Myeloma(12/21/2009) Researchers affiliated with the Nordic Myeloma Study Group have reported that patients who have received an autologous stem cell transplant for initial treatment of multiple myeloma have an improved response rate following Velcade® (bortezomib) consolidation compared with placebo. The details of this study were presented at the 2009 meeting of the American Society of Hematology (ASH) in New Orleans in early December.
Revlimid® Delays Progression of Multiple Myeloma After Stem Cell Transplantation(12/21/2009) At the 2009 meeting of the American Society of Hematology (ASH) in New Orleans in early December, researchers affiliated with the Phase III Intergroup Study CC-5013 reported that maintenance Revlimid® (lenalidomide) decreased recurrences by 58% in patients with multiple myeloma receiving a single autologous stem cell transplant. Other Phase II and III studies at ASH also addressed the efficacy of post-transplant Revlimid maintenance in patients with multiple myeloma.
Complete Remission Predicts for Long Survival of Patients with Multiple Myeloma(3/12/2010) Researchers from the M. D. Anderson Cancer Center have reported that achieving a complete remission (CR) was the dominant prognostic factor for long survival of patients with multiple myeloma (MM). The details of this large retrospective review were published in the March 2010 issue of Bone Marrow Transplantation.
Velcade® Effective in Patients with Systemic Amyloidosis(1/27/2010) Researchers from Greece, the UK, and Italy have reported that Velcade® (bortezomib) with or without dexamethasone is active for treatment of primary systemic light chain amyloidosis. The details of this study appeared in an early online publication in the Journal of Clinical Oncology on January 19, 2010.
Velcade® Consolidation Improves Response Rate After High-dose Melphalan for Myeloma(12/21/2009) Researchers affiliated with the Nordic Myeloma Study Group have reported that patients who have received an autologous stem cell transplant for initial treatment of multiple myeloma have an improved response rate following Velcade® (bortezomib) consolidation compared with placebo. The details of this study were presented at the 2009 meeting of the American Society of Hematology (ASH) in New Orleans in early December.
Revlimid® Delays Progression of Multiple Myeloma After Stem Cell Transplantation(12/21/2009) At the 2009 meeting of the American Society of Hematology (ASH) in New Orleans in early December, researchers affiliated with the Phase III Intergroup Study CC-5013 reported that maintenance Revlimid® (lenalidomide) decreased recurrences by 58% in patients with multiple myeloma receiving a single autologous stem cell transplant. Other Phase II and III studies at ASH also addressed the efficacy of post-transplant Revlimid maintenance in patients with multiple myeloma.
New Proteasome Inhibitor, Carfilzomab, Has Significant Activity in Relapsed Myeloma(10/6/2009) Researchers affiliated with the Multiple Myeloma Research Consortium (MMRC) have reported that carfilzomab monotherapy is highly active in patients with relapsed myeloma and can be administered safely for at least one year in responding patients. The details of this study were presented at the Joint ECCO 15-34th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.
Revlimid®-based Regimen with Neulasta® Support Very Effective for Relapsed Myeloma(3/18/2009) Researchers affiliated with the German Myeloma Study Group have reported that a regimen of Revlimid® (lenalidomide), Adriamycin® (doxorubicin), and dexamethasone supported by Neulasta® (pegfilgrastim) resulted in a 74% complete or very good partial remission rate in patients with relapsed and refractory multiple myeloma. The details of this study appeared in an early online publication in Blood of January 30, 2009.
Revlimid®, Melphalan, Prednisone, and Thalomid® Effective for Relapsed Myeloma(3/3/2009) Researchers from Italy have reported that the combination of Revlimid® (lenalidomide), melphalan, prednisone, and Thalomid® (thalidomide) results in a 76% response rate in patients with relapsed or refractory multiple myeloma. The details of this study were presented on December 9 at the 2008 meeting of the American Society of Hematology.
New Agents for the Treatment of Multiple Myeloma Presented at ASH 2008(1/23/2009) At the 2008 meeting of the American Society of Hematology in San Francisco in December, there were several oral presentations of new and promising agents for the treatment of patients with multiple myeloma.
Velcade® and Perifosine Effective in Relapsed Multiple Myeloma Previously Treated with Velcade(1/22/2009) Researchers from several U.S. institutions have reported a 40% overall response rate to the combination of perifosine and Velcade® (bortizomib) in patients with multiple myeloma who had been previously treated with Velcade. The details of this study were presented at the 2008 meeting of the American Society of Hematology on December 9 in San Francisco.
Patient Home
